Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.
Reinhart K, Wiegand-Löhnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willatts S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J.
Crit Care Med. 1996 May;24(5):733-42. Erratum in: Crit Care Med 1996 Sep;24(9):1608. PMID: 8706447 [PubMed - indexed for MEDLINE]Related articles